Diagnostic significance of detecting dysgranulopoiesis in XXXX .

@entity854 @entity9638 @entity1860 @entity706
We examined whether the detection of dysgranulopoiesis in blood or bone marrow would predict @entity1860 ( @entity1860 ) in transformation in 31 cases that fulfilled World Health Organization criteria for disease transformation, including 14 in accelerated phase (AP), 10 in @entity9638 ( @entity9638 ), and 7 in @entity706 ( @entity706 ). Dysgranulopoiesis was detected in 7 cases, 6 in AP and 1 in @entity9638 , but not in @entity706 or chronic phase cases. In 3 AP cases, dysgranulopoiesis was identified 2 to 5 months before the morphologic diagnosis of transformation. Two AP cases showed no dysgranulopoiesis in previous blood or marrow smears. For 2 cases (1 AP and 1 @entity9638 ), no previous blood or marrow specimens were available. Cytogenetic information was available for 6 of 7 cases with and 22 of 24 cases without dysgranulopoiesis. All cases with dysgranulopoiesis had secondary chromosome abnormalities in addition to t(9;22). In 5 (83%) of 6 cases with dysgranulopoiesis, the secondary chromosome abnormalities included @entity854 . In contrast, none of the 22 cases of @entity1860 in AP or BC but without dysgranulopoiesis showed 17p abnormalities (P = .001). Our findings demonstrated that dysgranulopoiesis was associated strongly with chromosome 17p abnormalities and may indicate the onset of or impending disease transformation.
